Gemcitabine-docetaxel as first-line intravesical therapy when BCG is not available

Design

Prospective single-arm, open-label phase 2 trial

Population

25 patients with BCG-naive high-risk non-muscle-invasive bladder cancer

Primary outcome

High-grade recurrence-free survival (secondary endpoints at 24 and 36 months)

Effect

84% at 24 months; 80% at 36 months (95% CI 58% to 91%); no progression on treatment

This single-arm phase 2 trial, with three-year results published in June, gave intravesical gemcitabine and docetaxel weekly for six weeks, then monthly for two years, to 25 patients with BCG-naive high-risk non-muscle-invasive bladder cancer. Most had T1 high-grade disease and over a third had carcinoma in situ.

High-grade recurrence-free survival was 84% at two years and 80% at three (95% CI 58% to 91%). No patient progressed during treatment and two eventually had cystectomy. Of seven high-grade recurrences, six were treated with BCG afterwards. A fifth of patients had a grade 3 adverse event, mainly haematuria and infection.

The numbers are small and there is no BCG comparison; randomised trials are under way. BCG remains the standard of care.

But BCG supply has been interrupted repeatedly, including in India. For a patient with high-risk disease who cannot get BCG, these data support gemcitabine-docetaxel as a reasonable alternative rather than leaving them untreated or moving straight to cystectomy.

• BCG remains first-line for high-risk non-muscle-invasive bladder cancer
• Consider intravesical gemcitabine-docetaxel when BCG is unavailable
• Use induction plus maintenance, as in the trial schedule
• Watch for haematuria and urinary infection during treatment
• Continue cystoscopic surveillance as for BCG-treated patients

Why it matters

It gives a documented option for high-risk patients during BCG shortages.

Don't overread it

A 25-patient single-arm trial cannot show equivalence to BCG; guidelines have not changed.

The statistics, in plain English

80% recurrence-free at three years is 20 of 25 patients. The confidence interval from 58% to 91% is wide because the trial is small, and without a control arm it cannot show how it compares with BCG.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.